The sentinel lymph node status is an important factor for predicting clinical outcome in patients with stage I or II cutaneous melanoma

Cancer

Volumn 91, Issue 12, 2001, Pages 2401-2408

  Muller, Markwin G Statius ^a   Van Leeuwen, Paul A M ^a   De Lange de Klerk, Elly S M ^b   Van Diest, Paul J ^a   Pijpers, Rik ^a,b   Ferwerda, Charlotte C ^a   Vuylsteke, Ronald J C L M ^a   Meijer, Sybren ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Breslow thickness; Disease free survival; Logistic regression; Lymphatic invasion; Melanoma; Prognosis; Sentinel lymph node procedure; Ulceration

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENDER; HUMAN; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; SKIN ULCER; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; REGRESSION ANALYSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 0035876070     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010615)91:12<2401::AID-CNCR1274>3.0.CO;2-I     Document Type: Article

References (31)

1. Surgical management of regional lymph nodes in cutaneous melanoma
2. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities
3. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients
4. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO melanoma programme
5. Malignant melanoma: Mayo Clinic experience
6. Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients
7. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia
8. Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991
9. The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm)
10. Technical details of intraoperative lymphatic mapping for early stage melanoma
11. Minimal-access surgery for staging of malignant melanoma
12. Historical perspective of lymphatic tumour spread and the emergence of the sentinel node concept
13. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy
14. Sentinel node biopsy in melanoma patients: Dynamic lymphoscintigraphy followed by intraoperative gamma probe and vital dye guidance
15. Pathological investigation of sentinel lymph nodes
16. Are locoregional cutaneous metastases in melanoma predictable?
17. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial. Multicenter Selective Lymphadenectomy Trial Group
18. The sentinel node procedure in cutaneous melanoma: An overview of 6 years' experience
19. Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma
20. Systemic adjuvant treatment of high-risk melanoma: The role of interferon alfa-2b and other immunotherapiesz
21. Epidemiology of malignant melanoma
22. Melanoma nodal metastases: Biologic significance and therapeutic considerations
23. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients
24. Loco-regional melanoma. I. Natural history
25. Cutaneous malignant melanoma in West Yorkshire. II. A prospective study of recurrence and prediction of lymph nodal metastasis
26. Recurrent malignant melanoma: The identification of prognostic factors to predict survival
27. A new American Joint Committee on cancer staging system for cutaneous melanoma
28. A prognostic model for predicting 10-year survival in patients with primary melanoma. The Pigmented Lesion Group
29. Predicting ten-year survival of patients with primary cutaneous melanoma: Corroboration of a prognostic model
30. Malignant melanoma. Prognostic significance of "microscopic satellites" in the reticular dermis and subcutaneous fat
31. Predicting outcome in patients with localized melanoma